It was a multicenter, open-label, Bayesian trial nested within the CORIMUNO-19 cohort, in patients with moderate-to-severe COVID-19, neither receiving mechanical ventilation nor admitted at ICU, and with a CRP >25 mg/L. This evidence concerns the gene CRP and COVID-19.